SEC Form 4 · accession 0001209191-18-020014
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas J. Sarlis
Officer — Chief Medical Officer and SVP
Period of report
Mar 13, 2018
Accepted (ET)
Mar 15, 2018 · 7:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $5.24 | Mar 13, 2018 | A | 70,000 | A | — | Mar 12, 2028 | Common Stock | 70,000 | 70,000 | D |
Explanation of responses
- F1One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 13, 2018 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.